SemaVerified Editorial Policy: Medical Review & Content Standards

Who We Are

SemaVerified is an independent research platform. We are not a clinic, a telehealth company, a pharmacy benefit manager, or an insurance broker. We have no ownership stake in any semaglutide provider and receive no compensation from any clinic based on the content of our research, rankings, or recommendations.

Our mission is straightforward: give patients in the Dallas-Fort Worth area clear, accurate, independently verified information about semaglutide treatment options — pricing, clinic credentials, insurance coverage, and access programs — so they can make informed decisions without having to navigate a market full of promotional content designed to convert rather than inform.

The SemaVerified research team combines backgrounds in health data research, pharmacy practice, and investigative journalism. Our core process involves direct outreach to clinics, primary source verification against official regulatory databases, and medical review of every factual claim before a page is published. We apply the same verification standard to a $249/month clinic as we do to a $400/month clinic. We have no incentive to favor any provider over another, and our editorial policies are designed to keep it that way.

SemaVerified launched in 2026 to address a specific gap: the Dallas-Fort Worth semaglutide market has expanded rapidly, with 40+ clinics now operating across 14 cities, but patients had no reliable, independent source to compare options. We built the resource we wished existed.

Medical Reviewer

All SemaVerified content is reviewed by Dr. Sarah Mitchell, PharmD, a licensed clinical pharmacist, before publication. Dr. Mitchell holds a Doctor of Pharmacy degree and is licensed in the state of Texas through the Texas State Board of Pharmacy (TSBP). Her clinical focus includes pharmacotherapy for metabolic disease, GLP-1 receptor agonist therapy, and patient education for chronic weight management.

Dr. Mitchell's review role is independent. She is retained as a medical advisor, not as an employee, and her compensation is a flat fee per review — not tied to publication outcomes, page traffic, or advertiser relationships. She has no financial relationship with any clinic or provider listed on SemaVerified.

What Dr. Mitchell Reviews

Before any page is published, Dr. Mitchell evaluates the following:

• Clinical accuracy. Are drug names, mechanisms, dosing schedules, and pharmacology descriptions correct and consistent with current prescribing information?
• Regulatory compliance. Does the content accurately describe FDA drug approval status, shortage designations, compounding regulations under Sections 503A and 503B of the FD&C Act, and Texas-specific pharmacy board rules?
• Appropriate scope. Does any content cross the line from patient education into clinical advice? SemaVerified educates patients about treatment options; it does not prescribe, diagnose, or recommend specific treatments for individual patients. Dr. Mitchell flags and removes any language that could be construed as individualized medical advice.
• Risk disclosure. Are material risks — including the quality variance in compounded semaglutide, the regulatory uncertainty around compounding when shortage status ends, and contraindications — disclosed accurately and prominently?
• Source credibility. Are clinical claims sourced to primary literature, official regulatory documents, or peer-reviewed research? Dr. Mitchell reviews source quality and flags secondary claims that need stronger attribution.

Medical review is not a rubber stamp. Dr. Mitchell has editorial authority to require changes to any page before it publishes. Pages that cannot be brought into compliance are not published.

Editorial Process

Every page on SemaVerified passes through a five-stage process from initial research to publication. No stage is skipped, and no page is published until all five are complete.

Stage 1: Research

The research team identifies the topic scope and begins primary source collection. For clinic-specific pages, this means direct outreach to every provider in the dataset: phone calls, website verification, and review of published pricing pages. For regulatory or clinical topics (FDA shortage status, insurance coverage rules, drug interactions), we pull directly from primary sources — FDA databases, carrier formularies, Texas Medical Board records, and published clinical trials. We do not rely on press releases, clinic marketing materials, or unverified third-party aggregators as primary sources. Research for a comprehensive DFW pricing page typically requires 40+ individual data points verified through direct contact.

Stage 2: Writing

A SemaVerified writer drafts the page against a structured brief that specifies the required sections, word count targets, mandatory disclosures, and source requirements. Every factual claim in the draft is tagged with a source citation before the draft advances to review. Writers are instructed to present information neutrally — no promotional framing, no language that favors paid partners over editorial content, and no health claims that are not supported by the cited source.

Stage 3: Medical Review

The draft is submitted to Dr. Sarah Mitchell for medical review. As described in the Medical Reviewer section above, she evaluates clinical accuracy, regulatory compliance, scope appropriateness, risk disclosure, and source credibility. Revisions requested by Dr. Mitchell are non-negotiable. The page does not advance until she has reviewed the final revised draft and cleared it for publication.

Stage 4: Fact-Check

A separate team member who did not write the draft performs a line-by-line fact-check against the cited sources. Each cited statistic, claim, and regulatory statement is verified against the original source document. Any discrepancy — even a minor one — is resolved by returning to the primary source. This stage catches sourcing errors, outdated data, and claims that have been paraphrased inaccurately. Clinic-specific data (addresses, phone numbers, current pricing) is re-verified by direct contact at this stage, not taken from the writer's original notes.

Stage 5: Publish

The page is published with a visible publication date and a "last verified" date that reflects when the data was most recently confirmed. The page enters the update rotation described in the Update Cadence section below.

Update Cadence

SemaVerified pages are not static. The semaglutide market changes: clinics open and close, prices shift, the FDA updates its shortage status, and insurance formularies change annually. Our update schedule is designed to keep the information patients rely on accurate without treating every minor change as a reason to republish.

Monthly Updates: Pricing & Clinic Status

Every first week of the month, we re-verify pricing and operational status for every clinic in our DFW dataset. This involves direct contact with each provider — phone, email, or website review — to confirm current pricing and that the clinic remains open and accepting new patients. Any pricing change of $10 or more is reflected in the relevant page immediately. Clinic closures, paused intake, or changes in offered medications trigger an update within 48 hours of confirmation. The "last verified" date on every page reflects when this monthly check was completed.

Quarterly Updates: Full Content Review

Every quarter, every published page undergoes a full editorial review: the complete research stage is repeated, sources are re-checked for currency, regulatory language is reviewed against any FDA or Texas regulatory updates, and the medical reviewer re-approves the page for the next quarter. Quarterly reviews also include new clinic discovery — we actively search for providers that have entered the market since the last review and add them to our dataset if they meet our inclusion criteria. Any clinic identified during a quarterly sweep is verified through the same five-stage process as the original content before being added.

Annual Updates: Regulatory Review

Each January, we conduct a full regulatory review of all content. This includes a review of any changes to FDA compounding rules, updates to the Texas Medical Board's scope-of-practice regulations, changes to state Medicaid formularies, and any new clinical trial data that materially changes the evidence base for statements we have made about semaglutide efficacy, safety, or comparative effectiveness. The annual regulatory review is conducted in consultation with Dr. Mitchell and may result in substantive content changes to multiple pages.

When changes are material — meaning they could affect a patient's decision about treatment — we note them prominently at the top of the updated page.

Conflict of Interest Disclosure

SemaVerified's business model is designed around a structural separation between editorial content and commercial relationships. We disclose that model fully here.

What We Do Not Do

No clinic pays for inclusion in our database, our clinic comparison tables, or any other editorial content. No clinic pays for favorable rankings, positive descriptions, or preferential placement in our content. No clinic has editorial input into how they are described. Our editorial team does not accept gifts, free consultations, or any other compensation from providers we cover. These are non-negotiable policies, not aspirational guidelines.

Our Current Revenue Model

SemaVerified is currently a pre-revenue research project. We have no commercial relationships with any clinic, insurer, pharmacy benefit manager, or pharmaceutical manufacturer as of the publication date of this policy.

Our Planned Revenue Model

SemaVerified's planned revenue model involves exclusive provider placements: the right for one clinic per vertical per city to be featured prominently as a "SemaVerified Preferred Provider" in a clearly marked, visually distinct placement that is separated from editorial content. When this model is active:

• Preferred Provider placements will be clearly labeled as paid placements on every page where they appear. Patients will never have to wonder whether a featured clinic paid for its position.
• Preferred Provider status will not affect a clinic's description, ranking, or inclusion in any editorial content, table, or comparison. A clinic that pays for a Preferred Provider placement will be described in our editorial content exactly as it would be if it did not pay.
• We will not accept Preferred Provider fees from any clinic that does not meet our baseline verification standards. Payment does not substitute for verification.
• This editorial policy page will be updated to reflect active commercial relationships at the time they begin.

The rationale for this model: we believe patients can handle transparent commercial relationships if they are disclosed clearly. What they cannot navigate is the current landscape of undisclosed paid placements, affiliate link structures disguised as research, and ranking systems driven by who pays the most. We disclose ours. We believe that distinction is meaningful.

Data Sourcing Standards

SemaVerified uses a tiered sourcing hierarchy. Primary sources are always preferred. Secondary sources are acceptable for context and background but are not the sole basis for specific factual claims. Tertiary and unverified sources are not used.

Primary Sources

Primary sources for SemaVerified content include: the Texas Medical Board for provider license verification; the Texas State Board of Pharmacy for pharmacy and pharmacist licensing; the FDA drug shortage database and official FDA guidance documents for regulatory status; clinic websites, published pricing pages, and direct phone or email contact with clinic staff for pricing and operational data; carrier formulary documents obtained directly from BCBS Texas, UnitedHealthcare, Aetna, Cigna, and Molina for insurance coverage; and the CDC, USDA, and Census Bureau for demographic and epidemiological data.

Secondary Sources

Secondary sources used for context and background include peer-reviewed clinical trial data (published in journals indexed in PubMed), manufacturer prescribing information, pharmacy benefit management industry reports from organizations like PBMI, and publicly filed earnings reports from publicly traded healthcare companies.

What We Do Not Use

SemaVerified does not use unverified patient reviews (Google, Yelp, Healthgrades) as factual sources. We do not use social media posts, Reddit threads, or forum discussions as the basis for clinical or pricing claims. We do not use content from other aggregator sites, lead generation pages, or clinic marketing materials as primary source data. If we cannot verify a claim through a primary source, we do not publish it.

Contact & Corrections

We take corrections seriously. If you are a patient, clinician, or clinic who has identified a factual error in our content — incorrect pricing, wrong clinic information, an outdated regulatory statement, or a clinical claim you believe is unsupported by the cited source — we want to hear from you.

Email our editorial team at editorial@semaverified.com. Include the URL of the specific page, the claim you believe is incorrect, and the source you believe supports the correction. We review all correction requests within 5 business days. If we confirm an error, we correct it and note the correction at the bottom of the updated page. We do not silently delete errors.

Clinics requesting review: If your clinic is not currently in our database and you would like to be considered for inclusion, email clinics@semaverified.com with your clinic name, address, and pricing. We review all requests on our quarterly new-clinic discovery schedule. Requesting inclusion does not guarantee it; inclusion requires passing our standard five-stage verification process. We do not expedite inclusion for clinics that pay or offer compensation of any kind.

Media and licensing inquiries: Contact hello@semaverified.com.